Medicxi appoints two Venture Partners

Medicxi, a European life sciences investment firm, has appointed Sanford (Sandy) Zweifach and Paul Sekhri as Venture Partners.

In their roles at Medicxi, Zweifach and Sekhri will leverage their strong track records of successful transactions and respective 30 plus years of experience stewarding life sciences companies to help steer Medicxi’s  portfolio companies to optimal growth and the best suited strategic transactions, as a number of molecules in development move to proof of concept stage, or enter the clinic.

 
Zweifach is currently the Chairman of Palladio Biosciences, and Executive Chairman of Janpix, two Medicxi portfolio companies. His focus is in corporate partnering, business development, operations, private and public investing, and capital raising. Sekhri is currently the President and CEO of eGenesis. He has been a director and/or Chairman of more than 27 private and public company boards, and his diverse background and experience includes leading companies with a focus on immunology. Please see their detailed biographies further below.
 
Francesco De Rubertis, co-founder and Partner at Medicxi, says: “We are delighted to have Sandy and Paul, two incredibly successful and transaction driven, senior professionals as part of an expansion to our team. In 2019, we closed the EUR400 million Medicxi III fund bringing the total amount raised by Medicxi in the last three years to over USD1 billion. Their appointment underscores our ongoing commitment to strengthen our platform to help entrepreneurs deliver on their product visions.” 
 
Zweifach says: “I am very excited to be working with the team of scientific and medical experts at Medicxi. I look forward to adding my business experience to their outstanding medicinal scientific insight to further tailor and build on their enviable track record of investments.”
 
Sekhri adds: “Having known the Medicxi team for over 25 years, I have been following their progression, and am incredibly impressed with their growth from an early stage start up fund to what is clearly now one of the leading life sciences investment firms. I look forward to working with the team, bringing business and commercial value to their future transactions.”